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Abstract
Context: The incidence of localised prostate cancer is increasing worldwide. In light of recent
evidence, current, radical, whole-gland treatments for organ-confined disease have being
questioned with respect to their side effects, cancer control, and cost. Focal therapy may be an
effective alternative strategy.
Objective: To systematically review the existing literature on baseline characteristics of the
target population; preoperative evaluation to localise disease; and perioperative, functional,
and disease control outcomes following focal therapy.
Evidence acquisition: Medline (through PubMed), Embase, Web of Science, and Cochrane
Review databases were searched from inception to 31 October 2012. In addition, registered
but not yet published trials were retrieved. Studies evaluating tissue-preserving therapies in
men with biopsy-proven prostate cancer in the primary or salvage setting were included.
Evidence synthesis: A total of 2350 cases were treated to date across 30 studies. Most studies
were retrospective with variable standards of reporting, although there was an increasing
number of prospective registered trials. Focal therapy was mainly delivered to men with low
and intermediate disease, although some high-risk cases were treated that had known,
unilateral, signiﬁcant cancer. In most of the cases, biopsy ﬁndings were correlated to speciﬁc
preoperative imaging, such as multiparametric magnetic resonance imaging or Doppler
ultrasound to determine eligibility. Follow-up varied between 0 and 11.1 yr. In treatment-
naı¨ve prostates, pad-free continence ranged from 95% to 100%, erectile function ranged from
54% to 100%, and absence of clinically signiﬁcant cancer ranged from 83% to 100%. In focal
salvage cases for radiotherapy failure, the same outcomes were achieved in 87.2–100%,
29–40%, and 92% of cases, respectively. Biochemical disease-free survival was reported using
a number of deﬁnitions that were not validated in the focal-therapy setting.
Conclusions: Our systematic review highlights that, when focal therapy is delivered with
intention to treat, the perioperative, functional, and disease control outcomes are encouraging
within a short- to medium-term follow-up. Focal therapy is a strategy by which the
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The advent of prostate-specific antigen (PSA) screening has
led to stage, grade, and risk migration towards diagnosis of
less aggressive prostate cancer (PCa). As a result, men with
localised PCa and physicians who advise them face a
difficult therapeutic dilemma: surveillance versus radical
whole-gland therapy. The available evidence from random-
ised controlled trials (RCTs) demonstrates that there is little
to no difference between these choices in terms of overall
and cancer-specific survival after a median of 10 yr of
follow-up [1]. In light of these findings, the patient’s
dilemma is made that much more profound by the
significant rates of genitourinary and rectal side effects,
which can occur despite technological improvements in
surgery and radiation [2–5].
Consequently, there has been interest in focal therapy.
This tissue-preserving strategyhasat its core the reductionof
treatment-related toxicity by minimising damage caused to
the prostate and adjacent structures while attempting to
retain the benefits of treating cancer [6–9]. This is an
approach adapted by many other solid-organ malignancies,
including renal, thyroid, breast, liver, and pancreas, but in
whichPCahas limitedevidenceandacceptance. Indeed, since
whole-mount analysis of radical prostatectomy specimens
has shown the presence of multiple foci of disease in most
cases, theperceptionhasbeenthatwhole-glandtherapiesare
mandatory.However, newevidence suggests that thenatural
history of the disease is predominantly driven by the largest
lesionwith the highest grade, the so-called index lesion [10].
Therefore, targeted treatment delivered to the index lesion
while sparing the rest of theglandmaybea rational approach
in men with intermediate- and low-volume, high-risk PCa
that has disease suitable for a focal tissue-preserving
approach. This proposition could make focal therapy
achievable in the majority of men with localised PCa.
At themoment, any approach able to preserve part of the
prostatic tissue (eg, ‘‘hockey stick’’ ablation, hemiablation,
and focal ablation) is considered focal therapy. Many groups
have published limited data on outcomes following focal
therapy, and many others are actively engaged or consider-
ing prospective comparative effectiveness research in this
area. It is an opportune time for a systematic review to
evaluate the current evidence base and identify strengths
and weaknesses and points of uncertainty about focal
therapy to guide future trials.
2. Evidence acquisition
This systematic review was performed according to the
Preferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) guidelines. We limited our sys-
tematic search to studies reporting on actual focal-therapy
outcomes. We report on the following specific categories
of data from the identified literature: (1) definition of the
ideal candidate for focal therapy, (2) disease localisation,
(3) identification ofwhich lesions to target, (4) definitions of
success and failure in focal therapy, and (5) morbidity and
cancer-control outcomes after focal therapy.Studies were identified by electronic search of Medline
(through PubMed), Embase, Web of Science, and Cochrane
Review databases from inception of the each respective
database through 31 October 2012, with prespecified
English language and human-studies restrictions. In addi-
tion, registered trials were retrieved from trials registries
(ClinicalTrials.gov and the International Standard Random-
ised Controlled Trial Number). We conducted a search of
ongoing trials to allow us to determine the current thinking
on patient eligibility, disease localisation, and types of
outcome measures that investigators in this area are
currently using. The search strategy was as follows:
‘‘PCa’’ OR ‘‘prostatic neoplasms’’ AND ‘‘focal treatment’’
OR ‘‘focal therapy’’ OR ‘‘tissue-preserving/-preservation’’ OR
‘‘subtotal’’ OR ‘‘cryosurgery’’ OR ‘‘cryotherapy’’ OR ‘‘cryoa-
blation’’ OR ‘‘high-intensity focused ultrasound ablation’’
OR ‘‘HIFU’’ OR ‘‘photodynamic therapy’’ OR ‘‘PDT’’ OR ‘‘laser
therapy’’ OR ‘‘brachytherapy.’’
RCTs, prospective development studies, and retrospec-
tive case series investigating ablative techniques to treat
biopsy-proven PCa in a subtotal manner in the primary or
salvage setting were included. Eligibility was reviewed
separately by two reporters (M.V. and H.U.A.). In case of
disagreement despite further discussion between the two
authors, the senior author (T.J.P.) arbitrated. All selected
articles were fully reviewed, and data extraction was
predefined pro forma. Authors of included studies were
contacted when one of the outcomes was not clearly or
explicitly reported or when there were concerns about
duplicate data sets; one reminderwas sent for nonreplies. In
cases where no reply was received, we chose not to report
uncertain outcomes. When two or more series completely
overlapped in time, only the largest series was reported;
when the overlapping was partial over a limited time, all
studies were reported, and the possible duplication of data
was highlighted in the tables.
The primary endpointwas treatment-related side effects.
We defined these in the followingmanner and differentiated
them based on those reported by physicians and those using
validated patient-reported questionnaires: leak-free conti-
nence, leak-free andpad-free continence, erections sufficient
for penetration, and rectal toxicity (diarrhoea, bleeding, pain,
rectourethral fistula). Functional outcomes were extracted
from each study only when preoperative and postoperative
data were available. In other words, only patients with
normal function before treatment were considered. For
instance, when calculating erectile function outcome, the
denominator was represented by the men potent before the
operation. Secondary end points were failure defined by
residual PCa in the treatment area proven by biopsy, overall
complications, quality of life (QOL) outcomes, need for
secondary local or systemic treatment, and mortality.
Biochemical outcomes also were reported.
The following data were extracted from each study: Predefined eligibility criteria
 Participants, including sample size, age, D’Amico or
National Comprehensive Cancer Network cancer Risk
classification, PSA level, and Gleason grade
E U RO P E AN URO LOG Y 6 6 ( 2 0 1 4 ) 7 3 2 – 7 5 1734 P[(Fig._1)TD$FIG]reoperative diagnostic tools, such as imaging and biopsy
techniques used to localise disease Type of intervention, including ablation modality, type of
focal therapy, type of anaesthesia, and length of hospital
stay Follow-up duration
 Toxicity
 Cancer-control measures, including histology (divided
into for cause and protocol biopsy based on whether
biopsieswere conducted on suspicionof failureorwhether
the protocol required biopsies in allmen, respectively) and
biochemical disease-free survival (using current, nonva-
lidated definitions) PSA kinetics
 Need for additional treatments
 Metastatic disease
 Mortality.
Trifecta outcomes (pad-free continence, erections suffi-
cient for penetration with or without oral phosphodiester-
ase type 5 inhibitors [PDE5-Is], and disease control at last
follow-up) were extracted where possible.
The design of each study was reported according to the
Idea Development Evaluation Assessment and Long-term
(IDEAL) recommendations for evaluation of surgical inno-
vations, proposed by the Balliol Collaboration and based onRecords identified through
database searching
(n = 1871)
Records identif
clinical trial s
(n = 5
Records after duplicated removed
(n = 1489)
Records screened
(n = 1489)
Records assessed for eligibility
(n = 439)
Records included in qualitative synthesis
(n = 43)
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Fig. 1 – Preferred reporting items for systemathe UK Medical Research Council guidelines for evaluating
complex interventions [11]. The quality of studies was
assessed according to the level of evidence for therapy [12].
3. Evidence synthesis
3.1. Assessment of study quality
Overall, 43 studies were included; the selection process is
displayed in Figure 1. The quality of the evidence is low to
medium, with no study yielding a level of evidence >2b
(Table 1 and 2). Indeed, this classification system attributes
the quality mainly according to the study design; therefore,
only RCTs or systematic reviews of RCTs, which have not
been performed in focal therapy, are classified at higher
levels of evidence. Although this suggests that the results of
this review should be interpreted with caution, it should be
highlighted that several surgical techniques established in
clinical practice were based on similar levels of evidence
[13,14].
Twenty-five series in total were identified that evaluated
focal therapy in the primary setting (Table 1) [15–39]. This
equates to 2232 men treated using focal therapy and
reported in the literature. Six series used cryosurgery,
12 used high-intensity focused ultrasound (HIFU), 1 used
photodynamic therapy (PDT), 3 used photothermal therapy,ied through
earching
6)
Studies excluded with reasons
(n = 396):
Not relevant/did not meet criteria (n = 280)
Duplicate datasets (n = 19)
Preclinical studies (n = 5)
Review article (n = 49)
Experts’ comments or authors’ letters (n = 21)
Technical reports (n = 22)
Records excluded
(n = 1050)
tic review and meta-analysis flowchart.
Table 1 – Target population with stage of evaluation and level of evidence of 25 studies using focal therapy in the primary setting
Eligibility criteria
Reference Setting IDEAL
stage of
evaluation
Previous
treatment
Patients,
no.
Age, yr Preoperative
biopsy
Preoperative
imaging
Criteria for bDFS Spatial
location
PSA,
ng/ml
Gleason
score
Risk
classiﬁcation
(D’Amico
or NCCN)
Level of
evidence
Madersbacher
et al. [15]
Primary 1 NR 29 Mean: 64
(SD: 7.2)
NR NR NR Unilateral NR NR NR 2c
Zlotta
et al. [16]
Primary 1 NR 15 NR NR NR NR Organ conﬁned NR NR NR 2c
Beerlage
et al. [17]
Primary 1 NR 14 Mean: 62
(range: 55–69)
TRUS biopsy MRI
Bone scan
NR NR NR NR NR 2c
Souchon
et al. [18]
Primary 1 NR 2 NR NR MRI NR Organ conﬁned NR NR NR 2c
Moore
et al. [19]
Primary 1 No 6 Median: 66 (range:
61–71)
TRUS biopsy MRI
Bone scan
NR Organ conﬁned 15 3 + 3 NR 2c
Bahn
et al. [20]
Primary 2a NR 31 Mean: 63 (range or
SD: NR)
TRUS sextant biopsy plus target
biopsy of suspicious areas TRUS Doppler
evaluation
ASTRO Unilateral NR NR NR 4
Onik
et al. [21]
Primary 2a 25 (45%) received short-term
ADT (stopped at treatment)
55 NR TRUS 10-core biopsy or
transperineal template biopsy
NR ASTRO NR NR NR NR 4
Ellis
et al. [22]
Primary 2a NR 60 Mean: 69
(SD: 7.8)
NR NR ASTRO NR NR NR NR 4
Muto
et al. [23]
Primary 2a 7 (24.1%) received
short-term ADT (stopped
at treatment)
29 Median: 72 (range:
62–80)
TRUS >12-core biopsy MRI ASTRO Unilateral NR NR NR 3b
Murat
et al. [24]
Primary 2a NR 56 Mean: 65.6 (range or
SD: NR)
NR NR Phoenix Unilateral NR NR Low-
intermediate
4
Lindner
et al. [25]
Primary 1 No 12 Median: 56.5
(range: 51–62)
TRUS 12-core biopsy MRI NR Tumour located in
1 of 12 core
biopsy sectors
<10 3 + 3 Low 2c
Lindner
et al. [26]
Primary 1 NR 4 Median: 66 (range:
61–73)
NR NR NR NR NR NR NR 4
Raz
et al. [27]
Primary 1 NR 2 73 NR MRI NR NR NR NR NR 4
Truesdale
et al. [28]
Primary 2b No 77 Mean: 69.5
(SD: 6.7)
TRUS biopsy CT
Bone scan
Phoenix Unilateral NR NR NR 4
El Fegoun
et al. [29]
Primary 2a No 12 Mean: 70
(SD: 4.8)
NR CT
Bone scan
Phoenix Unilateral 10 3 + 4 Low-
intermediate
4
Ahmed
et al. [30]
Primary 2a No 20 Mean: 60.4
(SD: 5.4)
Transperineal template biopsy MRI NR Unilateral 15 4 + 3 Low-
intermediate
2b
Ward
et al. [31]
Primary 2b NR 1160 Mean: 67.8
(SD: 7.8)
NR NR ASTRO No
restriction
No
restriction
No
restriction
No restriction 4
Tay
et al. [32]
Primary 1 No 9 NR NR MRI NR NR <10 3 + 3 Low 4
Chopra
et al. [33]
Primary 1 No 8 Mean: 60 (range:
49–70)
TRUS 12-core biopsy MRI NR NR 15 4 + 3 Low-
intermediate
2c
Bahn
et al. [34]*
Primary 2b 13 (18%) received
short-term ADT (stopped
at treatment)
73 Median: 64
(range: 47–79)
TRUS sextant biopsy plus
mapping target biopsy of
suspicious areas
TRUS Doppler
evaluation
NR Unilateral 20 4 + 3 Low-
intermediate
4
Ahmed
et al. [35]
Primary 2a No 41 Median: 63 (range:
58–66)
Transperineal template biopsy MRI NR Unilateral and
bilateral
15 4 + 3 Low-
intermediate
2b
Dickinson
et al. [36]*
Primary 2a No 88 Median: 64 (range:
48–75)
Transperineal template biopsy MRI Phoenix and
Stuttgart
Unilateral and
bilateral
<20 4 + 3 Low-
intermediate
2b
Nguyen
et al. [37]
Primary 2b No 318 NR TRUS biopsy (sextant between
1997–2003, then 10–12 cores)
MRI Phoenix (and
Phoenix plus PSAV
>0.75/yr)
No tumour beyond
peripheral zone
< 15 3 + 4 Low-
intermediate
4
Napoli
et al. [38]
Primary 1 No 5 Median: 65.4
(range: 50–75)
NR MRI NR Unilateral and
unifocal
NR 4+ 3 Low-
intermediate
2c
Barret
et al. [39]
Primary 2b No 106 Mean: 66.5 (IQR:
61–73)
Transperineal template biopsy
(97%) and TRUS 12-core biopsy
(100%)
MRI NR Unilateral <10 3 + 3 Low 4
bDFS = biochemical disease-free survival; PSA = prostate-speciﬁc antigen; NCCN = National Comprehensive Cancer Network; NR = not reported; SD = standard deviation; TRUS = transrectal ultrasound; MRI = magnetic resonance imaging; ASTRO = American Society for Therapeutic
Radiology and Oncology; CT = computed tomography; ADT = androgen-deprivation therapy; PSAV = prostate-speciﬁc antigen velocity; IQR = interquartile range.
* This series partially overlaps with one previously reported.
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E U R O P E AN URO LOG Y 6 6 ( 2 0 1 4 ) 7 3 2 – 7 5 17361 used radiofrequency interstitial tumour ablation (RITA), 1
used magnetic resonance imaging (MRI)-guided brachy-
therapy, and 1 incorporated various ablation techniques.
Median follow-up periods for the reported focal therapy
series are 0–10.6 yr (overall range: 0–11.1 yr).
Table 2 summarises the eligibility criteria for patients
to be included in the five studies evaluating focal salvage
therapy in patients with biochemical failure after radical
whole-gland radiotherapy [40–44]. Apart from one feasi-
bility study investigating the role of RITA in a mixed
population of primary and salvage cases, cryoablation, HIFU,
and MRI-guided brachytherapy have all been evaluated in a
focal manner in patients after external-beam radiation
therapy (EBRT) and/or brachytherapy or after proton-beam
radiotherapy failure. The number of patients treated in this
manner across the series was 115, with a median follow-up
of 17–47 mo (range: 3–90 mo).
Thirteen registered trials are evaluating patients treated
by focal ablation, with an expected accrual of 989 men
[45–57]. These trials are using cryosurgery (three trials),
HIFU (three trials), PDT (three trials), irreversible electro-
poration (one trial), MRI-guided thermal therapy (one trial),
brachytherapy (one trial), and high dose-rate (HDR)
brachytherapy for external beam radiotherapy failure
(one trial) (Table 3).
3.2. Defining the ideal candidate for focal therapy
No overall consensus exists for defining the ideal candidate
for primary focal therapy, despite several consensus state-
ments. This reflects different schools of thoughtwith respect
to the role of focal therapy in PCa. In 2007, the International
Task Force on PCa proposed very conservative criteria for
selecting patients, essentially deeming focal therapy an
alternative to active surveillance in very low-risk disease
[58]. These criteriawereaPSA level<10ng/ml, theabsenceof
Gleason grade 4 and 5, the use of extended biopsy schemes,
and very restricted biopsy criteria, including maximum
length of cancer in each core of 7 mm and maximum
percentage of total coreswith cancer of 33%.Other consensus
groups have attempted to introduce greater flexibility in
these criteria by essentially allowing intermediate-risk and
some higher-risk PCas, effectively deeming focal therapy an
alternative strategy for those men who would normally be
advised to have radical therapy [7,59–61].
The criteria used to select candidates for focal therapy in
the primary setting do not reflect the conservative approach
initially laid down in 2007, and they show a predilection
towards intermediate-risk cancer as well as low-risk disease
(Table1).Most studieshaveexcludedpatientswithvery low-
risk disease and recruited men with presumed unilateral
disease. In summary, 1109men with low-risk disease (56%),
704menwith intermediate-risk disease (36%), and 164 men
with high-risk disease (8%) were treated with focal therapy
[15–39]. Risk categories were not available in 13 series. The
PSA level was 3.76–24 ng/ml (overall range: 0.01–82.2
ng/ml), and median age ranged from 56.5 to 73 yr (overall
range: 47–80 yr) among the studies. Individual Gleason
attribution was available in 20 series, with 1503 men with
Table 3 – The design of the ongoing 13 registered trials investigating focal therapy using various sources of energy
Eligibility criteria
Reference Leading
centre
Trial
number
Estimated
enrolment,
no.
Setting Technology Spatial
location
PSA level,
ng/ml
Gleason
score
Risk
classiﬁcation
(D’Amico
or NCCN)
Follow-up,
mo
Primary
outcome
(measure)
Secondary
outcome
(measure)
Stage Status (on
registration
system)
Eggener
[45]
University of
Chicago
NCT01192438 9 Primary MRI-guided laser-
induced thermal
therapy
NR NR 4 + 3 Low-
intermediate
6 Safety NR 2a Completed
(NR)
Taneja
[46]
NYU Urology
Associates
(multicentre)
NCT00946881 30 Primary PDT Unilateral tumour <10 3 + 3 Low 12 Safety - Cancer control
(biopsy)
- QOL outcome
2a Completed
(NR)
Emberton
[47]
University College
London Hospitals
(multicentre)
NCT00975429 86 Primary PDT NR <10 3 + 4 Low-
intermediate
6 Cancer
control
(biopsy)
- Urinary outcome
(IPSS)
- Erectile outcome
(IIEF)
- QOL outcome
2b Completed
(NR)
Emberton
[48]
University College
London Hospitals
(multicentre)
NCT01310894 200 Primary PDT Unilateral tumour 10 3 + 3 Low 24 Cancer
control
(biopsy)
- Urinary outcome
- Erectile outcome
- QOL outcome
2b Recruiting
Emberton
[49]
University College
London Hospitals
(multicentre)
NCT01194648 272 Primary HIFU Unilateral clinically
signiﬁcant disease
15 4 + 3 Low-
intermediate
36 Cancer
control
(biopsy)
- Urinary outcome
(IPSS and UCLA-EPIC
urinary domain)
- Erectile outcome
(IIEF-15)
- Rectal outcome
(UCLA-EPIC bowel
domain)
- QOL (EQ-5D and
RAND 36-item
Health Survey125)
2b Recruiting
Ahmed
[50]
University College
London Hospitals
NCT00987675 56 Primary HIFU Any localisation, but
preservation of at
least one
neurovascular
bundle
<20 8 All risks 12 Safety - Cancer control
(biopsy and PSA
kinetics)
- Urinary outcome
(IPSS and UCLA-EPIC
urinary domain)
- Erectile outcome
(IIEF-15)
- Rectal outcome
(UCLA-EPIC bowel
domain)
- QOL (FACT-P)
2a Recruiting
Guazzoni
[51]
Universita` Vita-
Salute San Raffaele
NCT00928603 100 Primary Cryoablation Tumours in the
transition zone are
excluded
<10 3 + 3 Low 60 Safety - Cancer control
- Urinary outcome
(IPSS)
- Erectile outcome
(IIEF-15)
- QOL (FACT-P and
MSKCC Prostate-
Health Related
Quality of Life
Questionnaire)
2b Recruiting
Napoli
[52]
University of Roma
La Sapienza
NCT01522118 12 Primary MRI-guided HIFU NR 10 3 + 4 Low-
intermediate
18 Safety - Cancer control
(biopsy)
2a Recruiting
Zelefsky
[53]
Memorial Sloan-
Kettering Cancer
Centre
NCT01354951 80 Primary Brachytherapy Unilateral tumour <10 3 + 4 Low-
intermediate
24 Safety
(NCI
CTCAE)
- Cancer control
(biopsy)
- QOL (MSKCC
Prostate-Health
Related Quality
of Life
Questionnaire)
2b Recruiting
Ward
[54]
UT MD Anderson
Cancer Centre
NCT00877682 100 Primary Cryoablation NR 10 3 + 4 Low-
intermediate
36 Cancer
control
(biopsy)
- Urinary outcome
- Erectile outcome
- Rectal outcome
- QOL outcome
2b Recruiting
Eastham
[55]
Memorial Sloan-
Kettering Cancer
Centre
NCT00774436 50 Primary Cryoablation NR <10 NR Low 6 Cancer
control
(biopsy)
- QOL 2b Not yet
recruiting
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E U R O P E AN URO LOG Y 6 6 ( 2 0 1 4 ) 7 3 2 – 7 5 1738Gleason score 6, 521 with Gleason score 7, and 82 men
with Gleason score 8.
In focal salvage series, patients were older, with the
median age ranging from 65 to 77 yr. Eighty-eight treated
men (76%) had failure following EBRT, 17 (15%) after
brachytherapy, 2 (2%) after brachytherapy combined with
EBRT, and 8 (7%) after proton beam therapy (Table 2). No
restriction in PSA value or initial risk classification was
applied in most studies. However, two series included only
patients with presumed unilateral disease [42,44].
Of the ongoing trials in the primary setting, four are
recruiting only low-risk disease, seven are recruiting low-
through intermediate-risk disease, and one has no risk
restriction (Table 3). Finally, one trial is evaluating focal
HDR brachytherapy after EBRT failure.
3.3. Disease localisation
The spatial location of the tumour within the prostate is
essential for focal therapy to deliver treatment. There is no
accepted standard for disease localisation for the purpose
of delivering focal therapy. The consensus group state-
ments in this area have made recommendations based
on limited information at the time of writing. Most have
recommended either extended transrectal ultrasound
(TRUS) biopsies with strict low-risk criteria or the use
of adjunctive imaging, usually multiparametric MRI
(mpMRI). Studies have shown that TRUS biopsy is
inaccurate for the purposes of identifying candidates for
focal therapy and for localising disease [62–70]. As a result,
most consensus statements have recommended that
transperineal template mapping biopsies (TTMBs) are
the gold standard for disease localisation for the purpose
of focal therapywhile accepting that this procedure ismore
invasive and has health-care resource implications, al-
though the risk of sepsis is negligible [71–79]. In addition,
there is no consensus as to howmanybiopsies are sufficient
to detect all or most clinically significant cancer. A recent
study has shown that TTMB using a 5-mm sampling frame
missed only one lesion from a total of 64 lesions that had a
volume of0.5 ml and/or had elements of Gleason pattern
4 on subsequent whole-mount radical prostatectomy
specimens [72].
Imaging in the form of a high-qualitympMRI reported by
expert radiologists may have the performance character-
istics required to localise significant areas of PCa. Evidence
is building to show that an area deemed negative onmpMRI
stands a 95% probability of having no clinically significant
disease as defined by the presence of any Gleason pattern
4 and/or a lesion volume of 0.5 ml [80,81]. Other
ultrasound modalities are demonstrating promise but
presently lack the weight of evidence for mpMRI [82–85].
In our systematic review, most of the studies used some
form of preoperative MRI in combination with biopsy
parameters as criteria to select patients; some recent series
use this modality for treatment planning (Table 4 and 5)
[27,32,33,37,38,41]. In summary, among the primary
selected studies, two series used only TRUS biopsy, two
used TRUS biopsy and Doppler ultrasound, six used TRUS
E U RO P E AN URO L OGY 6 6 ( 2 0 1 4 ) 7 3 2 – 7 5 1 739biopsy and MRI, and four used TTMB and mpMRI. The
preoperative assessment was not reported in 11 studies.
3.4. Identifying which lesions to target
PCa, as it is currently defined, is multifocal in about 80% of
cases on whole-mount pathology, especially if a finer
sampling frame of 3 mm is used [86]. This has generally
been regardedas amajor limitation in thewhole rationale for
focal therapy in PCa. Several areas of evidence suggest that
multifocality is not necessarily a limiting factor for tissue
preservation. First, multifocal disease is present in many
other cancers in which tissue-preserving therapy is now
standard care [87–90]. Second, for PCa, unilateral disease
is present in up to one-third of men who have surgery
[70,91–97]. Third, there has been increasing debate and
gradual acceptance that not all tumours in the prostate
behave similarly. The index-lesion concept proposes that it is
only thedominant lesion thatdrives thenatural historyof the
disease [98–101]. Indeed, this concept has been extended
further by stating that some lesions are clinically significant
(likely to have an impact on quality and longevity of life),
whereasothers are clinically insignificant [10,102–109].Men
whohave only clinically insignificant disease have little to no
chance of diseaseprogressionwithin their lifetime, and some
have proposed they would have no certain benefit in being
treated with active therapies [110].
Current trials have differed in the approach to ablative
strategies. Most investigators aim to treat all known areas of[(Fig._2)TD$FIG]
Fig. 2 – Different tissue-preserving strategies have been used across different s
strategies are shown in this representative scheme.cancer in a hemiablative fashion once a man’s PCa is
deemed unilateral. Some trials have deliberately allowed
for ablation of the index lesion alone even when multifocal
disease is found [49,50,56]. In reality, it is likely that the
difference among these trials is very small, since the studies
leaving behind untreated cancer for surveillance use biopsy
strategies, such as TTMB with 5-mm sampling, that have a
high sampling density. Consequently, in these studies, small
lesions, which are likely to be missed by other less accurate
sampling strategies, are located but are deliberately left
untreated.
In summary, all reported series have treated all known
areas of cancer, and no reported series have explicitly stated
that therapy was aimed at the index lesion and that lesions
were deliberately left untreated. Most ongoing trials aim to
treat all known areas of cancer, although three trials are
explicitly aiming treatment at the index or at clinically
significant lesions with surveillance of untreated insignifi-
cant lesions (Table 3).
In the largest series of 1160 men using cryoablation
and in another series using HIFU with multiple strategies
(n = 88), it was not possible to determine the extent of tissue
ablation per patient [31,36]. Either hemiablation or focal
ablation was used in the remaining studies: 12 used a
hemiablation or an extended ‘‘dog leg’’ or hockey stick
approach (n = 537; relative percentage: 49%), 16 used focal/
zonal ablation (n = 562; relative percentage: 51%), and
3 used bilateral focal ablation when multifocal disease was
present (n = 65; relative percentage: 6%) (Fig. 2).eries: (a) hockey stick, (b) hemiablation, (c) multifocal, and (d) unifocal
E U RO P E AN URO LOG Y 6 6 ( 2 0 1 4 ) 7 3 2 – 7 5 17403.5. Defining success and failure after focal therapy
Another major challenge in focal therapy is the definition
of what constitutes success and failure. The use of
disease-specific and overall mortality would require
large-scale RCTs, which would likely take 5 yr to recruit
and then 10–15 yr of follow-up to obtain sufficient event
rates to prove noninferiority over radical whole-gland
therapies or superiority over active surveillance. As a
surrogate, although PSA outcomes are accepted as a valid
outcome in standard therapies, the clinical utility of PSA
kinetics in tissue preservation is yet to be determined. Since
no PSA outcome measure has been validated in focal
therapy yet, the criteria used for defining radiotherapy
failure have been used across most of the studies. Thus, the
majority of the investigators have reported biochemical
outcomes using Phoenix or American Society for Therapeu-
tic Radiology and Oncology (ASTRO) criteria [111]. Howev-
er, these criteria are neither validated nor appropriate for
ablative techniques, not only because there is prostatic
tissue remaining but also because the mechanism of cell
death is different between radiation therapy and immediate
ablation, so PSA kinetics are likely to be different. Some have
proposed using the Stuttgart definition developed for
whole-gland HIFU [112]. One study investigated the
biochemical disease-free survival (bDFS) predictive value,
verified by follow-up biopsy, of Phoenix criteria alone or
Phoenix associated with PSA velocity <0.75 ng/ml per year
[37]. The authors found that the compound strategy could
predict biopsy-proven failure better than Phoenix criteria
alone. If PSA kinetics are used to define focal therapy
outcomes, it is likely that such models will have to
incorporate the fact that untreated tissue is still PSA
secreting and a threshold PSA for failure may have to
incorporate an estimation of the extent of prostatic tissue
ablated. However, until a validated PSAmeasure is found, an
international consensus is needed about what might
constitute biochemical failure after focal therapy, so that
medium-term outcomes can be used to allow comparison
between individual focal-therapy series, and between focal
therapy and standard care.
Our systematic review of focal-therapy series demon-
strates the summary outcomes presented in the following
section and in Table 4–7. Furthermore, Table 3 shows
outcomes used in prospective registered clinical trials that
have not yet been reported.
3.6. Current outcomes in respect of focal therapy in the primary
setting
3.6.1. Side effects, complications, and quality of life
Table 6 summarises the morbidity and functional outcome
of the studies selected. Median length of hospital stay was
1 d; other perioperative outcomes were poorly reported,
with only one study using a standardised classification of
these outcomes (Dindo-Clavien classification) [39]. The
incidences of the most frequent complications, namely,
urinary retention, urinary stricture, and urinary tract
infection, ranged from 0% to 17%, from 0% to 5%, and from0% to 17%, respectively. Only five studies actually reported
all of these [25,29,30,35,39].
Urinary functional outcomes were reported using
validated questionnaires in nine studies; physician-
reported rates were used in five studies. Using validated
questionnaires, the pad-free continence rate varied be-
tween 95% and 100%, and the range of leak-free rates was
83–100%.
Erectile function was reported using validated ques-
tionnaires in 10 studies and using physician-reported rates
in three studies. Considering only trials evaluating focal
therapy with intention to treat, when validated question-
naires were used, erectile function sufficient for penetration
was reported in 54–100% of patients (with orwithout PDE5-
I medication). Physician-reported rates ranged from 58.1%
to 85%.
Rectal toxicity was often poorly reported. When it was
reported, rates of fistula ranged from 0% to 1%; one series
reported one of 41 men suffering grade 3 rectal toxicity
conservatively managed as a possible rectourethral fistula
[35]. Finally, patient-reported outcomes evaluating overall
QOL were uncommonly used in these studies, with only
three publications reporting them.
3.6.2. Cancer control
Apart from early feasibility trials (n = 6) that verified the
effect of tissue ablation by analysis of radical whole-mount
prostatectomy specimens, nine series incorporated rou-
tine, mandatory, postfocal therapy biopsies in their
protocol. In the six early series, residual disease was
found in 73 of 74 men who had undergone radical
prostatectomy. Although this rate seems excessively high,
it should be noted that being early stage 0/1 trials, themain
objective was to assess the safety of the sources of energies
without actually attempting to ablate all the disease
present.
Of the remaining nine series, biopsies were performed
only on the treated side in three series; in the other six,
biopsy specimens also were taken on the contralateral side.
When post-therapy biopsy procedures were routinely
offered, clinically significant cancer was present in 0–17%
(n = 202). When clinically insignificant cancer also was
taken into account (excluding one feasibility trial that
evaluated safety rather than ablation), 4–50% of men had
positive biopsy results after treatment (n = 255). When
biopsy procedures were offered only for cause, overall
positive biopsy rates of 13–71% were demonstrated for all
types of cancer; when considering all patients enrolled in
these series, this percentage range was 3.7–23%. None of
these series reported the percentage of significant cancer
among patients undergoing a biopsy.
Two series evaluated the presence of residual tumour in
the treated area; this amounted to 3–14%when considering
only patients undergoing a biopsy and from 1.7% to 3.9%
when the denominator was all treated patients.
Biochemical control was reported using Phoenix criteria
in five series. Other definitions used were ASTRO (five
series), Stuttgart (one series), and Phoenix plus PSA velocity
>0.75 ng/ml per year (one series). The results range from
Table 4 – Actual population studied in each primary series with the histologic, biochemical, and cancer long-term outcomes
Reference Technology Type of
ablation
PSA
level,
ng/ml
Gleason
score at
preoperative
biopsy (%)
Risk
classiﬁcation,
D’Amico or
NCCN, no. (%)
Follow-up Postfocal
histology
(reason)
Presence of
any cancer,
actual (%)
Presence
of clinically
signiﬁcant
cancer
bDFS, % PSA
kinetics*
Secondary
treatment,
actual (%)
Metastatic
disease,
actual (%)
Mortality:
%
Madersbacher
et al. [15]
HIFU Midline target
or unilateral
ablation of
TRUS-visible
tumours
Mean: 24
(range: 2–82.8)
NR NR Few hours (mean/
median: NR)
RP 29/29 (100) NR NR NR NR NR Overall and
cancer-speciﬁc
survival: 100
Zlotta
et al. [16]
RITA Multifocal NR NR NR Mean/median: NR
(range: 0 d–3 mo)
RP 14/14 (100) NR NR NR NR NR Overall and
cancer-speciﬁc
survival: 100
Beerlage
et al. [17]
HIFU Total or
subtotal
hemiablation
Mean: 10.8
(range: 3.5–20)
NR NR Median: 8.5 d
(range: 7–12)
RP 13/14 (93)
4/14 (29) had
residual tumor
in treated area
NR NR NR 0/14 (0) 0/14 (0) Overall and
cancer-speciﬁc
survival: 100
Souchon
et al. [18]
HIFU Focal ablation
of peripheral
zone
NR NR NR NR NR NR NR NR NR NR NR NR
Moore
et al. [19]
PDT Focal with
ipsilateral
peripheral zone
ablation
Median: 6.95
(range: 1.9–15)
3 + 3: 6 (100) NR NR TRUS sextant
biopsy
(protocol)
6/6 (100) NR NR NR 4/6 (67) redo PDT
5/6 (83) salvage
treatment (3 EBRT,
1 brachytherapy,
1 cryotherapy)
0/6 (0) Overall and
cancer-speciﬁc
survival: 100
Bahn
et al. [20]
Cryoablation Hemiablation Mean: 4.95
(range or SD: NR)
6: 23 (74)
7: 8 (26)
NR Mean: 70 mo
(range: 2–107)
TRUS sextant
biopsy plus
target biopsy of
suspicious areas
on Doppler
(protocol)
1/25 (4) NR 92.9 NR 1/31 (4) redo
cryoablation
0/25 (0) Overall
survival: 96
Cancer-speciﬁc
survival: 100
Onik
et al. [21]
Cryoablation Focal Mean: 8.3
(range or SD: NR)
NR Low: 26 (48)
Intermediate:
20 (36)
High: 9 (16)
Mean: 3.6 yr
(range: 1–10)
NR Only patients
having biopsy:
4/30 (13)
All patients:
4/55 (7)
NR 95 (3 yr) Mean: 2.4
(SD: NR)
4/55 (7) redo
cryoablation
NR Overall and
cancer-speciﬁc
survival: 100
Ellis
et al. [22]
Cryoablation Hemiablation
plus contralateral
peripheral zone
(hockey stick)
Mean: 7.2 (SD: 4.7) 6: NR (78.3)
7: NR (20)
8 NR (1.7)
Low: 40 (66.7)
Intermediate:
14 (23.3)
High: 6 (10)
Median: 12 mo
(range: 3–36)
NR Only patients
having biopsy:
14/35 (40); 1/35
(3) in treated
side
All patients:
14/60 (23); 1/60
(1.7) in treated
side
NR 80.4 Median: 1.7
(IQR: NR)
11/60 (18) redo
cryoablation
0/60 (0) Overall and
cancer-speciﬁc
survival: 100
Muto
et al. [23]
HIFU Hemiablation
plus contralateral
peripheral zone
(hockey stick)
Median: 5.4
(range: 0.2–25.1)
Unknown: 2 (6.9)
6: 16 (55.2)
7: 6 (20.7)
8: 5 (17.2)
NR Median: 34 mo
(range: 8–45)
TRUS sextant
(protocol)
At 6 mo: 3/28
(10.7)
At 12 mo: 4/17
(23.5)
NR 2-yr
Low risk:
83.3
Intermediate
risk: 53.6
36-mo mean:
1.89 (SD: 1.51)
7/29 (24) ADT NR Overall and
cancer-speciﬁc
survival: 100
Murat
et al. [24]
HIFU Hemiablation NR NR Low: 33 (59)
Intermediate:
23 (41)
Median:
42 mo (NR)
NR NR NR 3 yr: 76
5 yr: 60
Nadir after
ﬁrst HIFU: mean:
0.5 (SD: NR)
Nadir after redo
HIFU: mean: 0.47
(SD: NR)
19/56 (34) redo
HIFU
NR NR
Lindner
et al. [25]
Photothermal
laser
Focal Mean: 5.7
(SD: 1.1)
3 + 3: 12 (100) Low risk:
12 (100)
6 mo TRUS 10-core
biopsy plus 2
cores guided in
the treated area
(protocol)
6/12 (50)
4/12 (33) in
treated area
2/12 (17) NR NR 1/12 (8) RP 0/12 (0) Overall and
cancer-speciﬁc
survival: 100
Lindner
et al. [26]
Photothermal
laser
Focal Median: 4.2
(range: 2.9–14.8)
3 + 3: 2 (50)
4 + 3: 2 (50)
NR 1 wk RP 4/4 (100) with
no residual
tumor in treated
area
NR NR NR NR NR Overall and
cancer-speciﬁc
survival: 100
Raz
et al. [27]
Photothermal
laser
Focal Median: 3.76
(range: 2.74–4.79)
3 + 3: 2 (100) Low: 2 (100) 1 mo NR NR NR NR NR 0/2 (0) NR Overall and
cancer-speciﬁc
survival: 100
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Table 5 – Actual population studied in each salvage series with the histologic, biochemical, and cancer long-term outcomes
Reference Technology Type of
ablation
PSA
level,
ng/ml
Gleason
score at
preoperative
biopsy (%)
Risk
classiﬁcation
(D’Amico or
NCCN)
Follow-up,
mo, median
no. (range)
Postfocal
histology
(reason)
Presence
of any
cancer
Presence of
clinically
signiﬁcant
cancer,
actual (%)
bDFS, % PSA kinetics
(at last
follow-up
unless
otherwise
stated)
Secondary
treatment,
actual (%)
Metastatic
disease,
actual (%)
Mortality, %
Shariat
et al. [40]
RITA Focal Median:
5.7 (range:
0.66–10.8)
Median: 7;
range: 6–8
NA 20 (3–38) TRUS 12-core biopsy
(protocol)
At 12 mo: 3/6 (50),
2/6 (33) in the
treated area
NR NR 90% experienced
a decrease in PSA
>50% (discrete
values: NR)
NR NR Overall and
cancer-speciﬁc
survival: 100
Nguyen
et al. [41]
MRI-guided
brachytherapy
Peripheral
zone
Median:
5.5 (range:
1.4–11.6)
2+3: 1 (4)
3+3: 18 (72)
3+4: 6 (24)
NA 47 (14–75) NR NR NR 4 yr: 70 NR NR NR NR
Eisenberg
et al. [42]
Cryoablation Hemiablation Median:
3.3 (range:
0.28–8.96)
NR NA 18 (6–33) TRUS biopsy
(protocol)
At 12 mo: 1/10 (10)
overall and in the
treated area
NR ASTRO
1 yr: 89
2 yr: 67
3 yr: 50
Phoenix
1 yr: 89
2 yr: 79
3 yr: 79
NR NR 3/15 (20) NR
Ahmed
et al. [43]
HIFU Hemiablation
(n = 16) or
quadrant
(n = 23)
Median:
3.3 (range:
0.02–27.9)
Unknown: 1 (3)
6: 2 (5)
7: 32 (82)
8: 4 (10)
NA 17 (10–29) Transperineal
template biopsy (for
cause)
Only patients having
biopsy:
4/9 (44)
All patients:
4/39 (10)
NR 2 yr:
Phoenix: 49
Stuttgart: 42
Median: 0.57
(IQR: 0.1–2.3)
16/39 (41)
had ADT
2/39 (5) NR
Abreu
et al. [44]
Cryoablation Hemiablation Median:
2.8 (range:
0–8.2)
3 + 3: 5 (20)
3 + 4: 6 (24)
4 + 3: 8 (32)
4 + 4: 6 (24)
NA 31 (4–90) TRUS sextant plus
mapping target
biopsy of suspicious
areas (protocol)
2/25 (8) 2/25 (8) 5 yr: 54 At 36 mo:
mean: 1.2
(SD: 1.6)
2/25 (8) No Overall and
cancer-speciﬁc
survival: 100
PSA = prostate-speciﬁc antigen; NCCN = National Comprehensive Cancer Network; bDFS = biochemical disease-free survival; RITA = radiofrequency interstitial tumour ablation; NA = not applicable; NR = not reported; TRUS = transrectal ultrasound; MRI = magnetic resonance
imaging; ASTRO = American Society for Therapeutic Radiology and Oncology; HIFU = high-intensity focused ultrasound.
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Table 6 – Perioperative and functional outcome of patients undergoing focal therapy in the primary setting
Reference Length
of stay, d,
median
Anaesthesia Complications,
actual (%)
Urinary
continence,
actual (%)
Erectile
function*,
actual (%)
Rectal
toxicity,
actual (%)
Quality
of life
Trifecta
outcome**,
actual (%)
Madersbacher et al. [15] NR General NR NR NR NR NR NR
Zlotta et al. [16] NR General
or spinal
NR NR NR NR NR NR
Beerlage et al. [17] 2 General
or spinal
NR NR NR Rectourethral ﬁstula: 0/14 (0)
Perineal pain: 14/14 (100)
Rectal bleeding: NR
Diarrhoea: NR
PROM: NR
NR NR
Souchon et al. [18] NR NR NR NR NR NR NR NR
Moore et al. [19] 1 General Urinary retention: 1/6 (17)
Urethral stricture: NR
UTI: 1/6 (17)
Outcome measure: NR
Pad free: NR
Leak free: 5/6 (83)
PROM: AUA-7
1/3 (33)
PROM: Brief Sexual
Function Inventory
Rectourethral ﬁstula:
0/3 (0)
Perineal pain: NR
Rectal bleeding: 2/6 (33)
Diarrhoea: 2/6 (33)
PROM: NR
NR NR
Bahn et al. [20] NR NR NR Pad free: 28/28 (100)
Leak free: NR
PROM: NR
24/27 (88.8)
PROM: Brief Male
Sexual Function
Index
NR NR NR
Onik et al. [21] NR NR NR Pad free: 24/25 (96)
Leak free: NR
PROM: NR
44/51 (85)
PROM: NR
NR NR NR
Ellis et al. [22] 1 NR NR Pad free: 55/55 (100)
Leak free: 53/55 (96.4)
PROM: NR
24/34 (70.6)
PROM: NR
(vacuum therapy
and oral therapy for
erectile dysfunction
offered
preoperatively)
Rectourethral ﬁstula: 0/34 (0)
Perineal pain: NR
Rectal bleeding: NR
Diarrhoea: NR
PROM: NR
NR NR
Muto et al. [23] 1 NR Urinary retention: NR
Urethral stricture 1/25 (4)
UTI 1/25(4)
Outcome measure: NR
Pad free: NR
Leak free: NR
PROM: UCLA-EPIC, IPSS
NR NR NR NR
Murat et al. [24] NR NR NR NR 28/52 (54)
PROM: IIEF-5
NR NR NR
Lindner et al. [25] 1 General Urinary retention: 0/12 (0)
Urethral stricture: 0/12 (0)
UTI: 0/12 (0)
Outcome measure: NR
Pad free: 12/12 (100)
Leak free: 12/12 (100)
PROM: IPSS
NR (100)
PROM: IIEF-5
Rectourethral ﬁstula: 0/12 (0)
Perineal pain: 3/12 (25)
Rectal bleeding: 0/12 (0)
Diarrhoea: 0/12 (0)
PROM: NR
NR 6/12 (50)
Lindner et al. [26] NR NR NR NR NR NR NR NR
Raz et al. [27] 1 General NR NR NR NR NR NR
Truesdale et al. [28] 1 General
or spinal
NR Pad free: 77/77 (100)
Leak free: NR
PROM: IPSS
NR
PROM: IIEF
NR NR NR
El Fegoun et al. [29] NR NR Urinary retention: 1/12 (8)
Urinary stricture: 0/12 (0)
UTI: 2/12 (16)
Outcome measure: NR
Pad free: 12/12 (100)
Leak free: NR
PROM: IPSS
NR NR NR NR
Ahmed et al. [30] 1 day General Urinary retention: 0/20 (0)
Urinary stricture: 1/20 (5)
UTI: 0/20 (05)
Outcome measure: NR
Pad free: 19/20 (95)
Leak free: 18/20 (90)
PROM: UCLA-EPIC, IPSS
19/20 (95)
PROM: IIEF-15
Rectourethral ﬁstula: 0/20 (0)
Perineal pain: NR
Rectal bleeding: NR
Diarrhoea: NR
PROM: FACT-P
No signiﬁcant
difference between
baseline and last
follow-up
PROM: FACT-P,
FACT-G
17/19 (89)
Ward et al. [31] NR NR Urinary retention:
6/518 (1.1)
Urinary stricture: NR
UTI: NR
Outcome measure: NR
Pad free: 499/507 (98.4)
Leak free: NR
PROM: NR
169/291 (58.1)
PROM: NR
Rectourethral ﬁstula: 1/507 (0.1)
Perineal pain: NR
Rectal bleeding: NR
Diarrhoea: NR
PROM: NR
NR NR
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Table 7 – Perioperative and functional outcome of patients undergoing focal therapy after radiotherapy failure
Reference Length of
stay, d,
median
Anaesthesia Complications,
actual (%)
Urinary
continence,
actual (%)
Erectile
function*,
actual (%)
Rectal toxicity,
actual (%)
Quality
of life
Trifecta
outcome**
Shariat et al. [40] 1 Sedation NR Pad free: NR
Leak free: NR
PROM: IPSS
NR NR Difference between
baseline and last
follow-up: No
PROM: Quality of
Life Index
NR
Nguyen et al. [41] 1 General Urinary retention: NR
Urethral stricture: 1/25 (4)
UTI: NR
Outcome measure: RTOG
Pad free: 22/25 (88%)
Leak free: NR
PROM: NR
NR Rectourethral ﬁstula: 3/25 (12)
Perineal pain: NR
Rectal bleeding: 2/25 (8)
Diarrhoea: NR
PROM: RTOG
NR NR
Eisenberg et al. [42] NR General
or spinal
Urinary retention: 0/15 (0)
Urethral stricture: 1/15 (7)
UTI: NR
Outcome measure: NR
Pad free: 14/15 (93.3)
Leak free: NR
PROM: NR
Ability to have
penetrative sex:
2/5 (40)
PROM: Sexual Health
Inventory for Men
Rectourethral ﬁstula: suspicion 1/15 (7)
Perineal pain: 1/15 (7)
Rectal bleeding: NR
Diarrhoea: NR
PROM: NR
NR NR
Ahmed et al. [43] 1 General Urinary retention: NR
Urethral stricture: 1/39 (3)
UTI: 3/39 (8)
Outcome measure:
Clavien-Dindo grade;
1: 3 (8), 2: 0, 3a: 1 (3),
3b: 9 (23), 4:0
Pad free: 34/39 (87.2)
Leak free: 25/39 (64.1)
PROM: UCLA-EPIC, IPSS
Ability to have
penetrative sex: NR
PROM: IIEF-15
Rectourethral ﬁstula: 1/39 (2.6)
Perineal pain: NR
Rectal bleeding: NR
Diarrhoea: NR
PROM: NR
NR NR
Abreu et al. [44] 1 NR NR Pad free: 25/25 (100)
Leak free: NR
PROM: NR
Ability to have
penetrative sex: 2/7
(29)
PROM: IIEF-5
Rectourethral ﬁstula: 0/25
Perineal pain: NR
Rectal bleeding: NR
Diarrhoea: NR
PROM: NR
NR NR
NR = not reported; PROM = patient-reported outcome measure; IPSS = International Prostate Symptom Score; RTOG = Radiation Therapy Oncology Group; UTI = urinary tract infection; UCLA-EPIC = University of California, Los Angeles-Expanded Prostate Index Composite.
* Ability to have penetrative intercourse.
** Pad-free, leak-free continence; erections sufﬁcient for penetration; absence of clinically signiﬁcant disease after focal therapy.
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[24,37].
Only 12 series reported the need for secondary focal
treatments, with a range of 0–34%. Salvage local treatments
were reported in 14 series with rates of 0–33%. One
feasibility trial had higher secondary focal (67%) and salvage
treatment (83%); these upper percentages were not
considered in the overall range, since the intent to treat
was not to destroy all tumour [19].
The progression to metastatic disease is not reported in
most of the studies, as the follow-up is too short to have a
significant percentage of patients develop metastasis.
Nevertheless, when it is indicated, it is extremely low
(0–0.3%).
Cancer-specific survival was extremely high in these
studies, as expected with the small numbers and short
follow-up inherent in almost all reported series; only three
studies had a follow-up>5 yr. Noman died of PCa after focal
therapy in the defined follow-up period. Four men died of
other causes in the follow-up period. The very lowmortality
rate was as expected with the short follow-up and the
inclusion of many men with low-risk disease, which has a
prolonged natural history.
3.7. Current outcomes of focal salvage therapy for failure after
radiation therapy
3.7.1. Side effects, complications, and quality of life
The toxicity and QOL outcomes for focal therapy after
radiation failure are reported in Table 7 from five published
series with a total of 115 men treated. The small numbers
considerably limit the generalizability of these findings.
Continence, estimated by pad-free rate, was achieved in
87.2–100% of patients. Erectile function was poorly
reported, possibly as a result of poor baseline function.
However, in three studies (n = 82), potencywas preserved in
29–40% of previously potent patients [42–44]. The rate of
rectourethral fistula (0–12%) was significantly higher than
in the primary cases.
3.7.2. Oncologic outcome
Follow-upwas amedian range of 17–47mo. Apart from one
feasibility trial, in which the positive biopsy rate for all
cancer was 50% in all areas and 33% in the treated area,
residual cancer was found in 8–10% of patients using TRUS
biopsy [40,42,44]. However, this percentage was as high
as 44% using TTMB, if considering only patients who had a
for cause biopsy as the denominator. When considering all
patients treated, the positive biopsy rate was 10% [43]. Only
one series reported the presence of residual significant
cancer, and it showed a rate of 8% [44].
Biochemical disease-free rates in the longest series using
the Phoenix criteria were 70% and 54% at 4 and 5 yr,
respectively [41,44]. In one series, the bDFS at 2 yr was
significantly lower at 42% using the Stuttgart criteria [43].
Salvage treatment was given to 8–41% of patients, and
metastatic diseasewas diagnosed in 5–20%. Overall survival
was 100% in the two series that reported this outcome
[40,44].4. Discussion
This systematic review highlights that when focal therapy
is delivered with intention to treat, the perioperative,
functional, and disease control outcomes are encouraging.
Although our systematic review was, by its nature,
thorough, there were areas that we could not evaluate but
that are pertinent to the debate surrounding focal therapy.
First, in the light of new findings regarding PCa pathology
and natural history, it appears clear that focal therapy
should targeted to patients who are likely to benefit from
active treatment, whereas men with clinically insignificant
disease should be monitored carefully by active surveil-
lance. Specifically, patients with clinically significant
disease localised only in one area of the prostate should
be considered the optimal candidates for a focal approach.
Second, accurate localisation of disease is essential with
mpMRI or novel ultrasoundmodalities with targeted biopsy
of suspicious areas, when available; equally, TTMBmay also
form part of a rigorous preoperative assessment.
Third, patients treated with an organ-preserving ap-
proach must be monitored with strategies similar to active
surveillance protocols. Indeed, the presence of significant
undetected disease, residual disease, cancer progression, or
de novo cancer are all possibilities that mandate active
monitoring. However, although the follow-up of men after
organ-sparing approaches requiresmeasuring the PSA level,
this will not sufficient by itself until validated biochemical
measures are developed. Biopsy of the treated and
untreated areas are required in the interim, although MRI
may play a role in the future if it can be validated for
detecting local failure against histologic outcomes.
Fourth, before focal therapy becomes an alternative
standard option across the board, it should be highlighted
that many issues remain to be addressed, including
determiningwhich ablative technology has better functional
andoncologic outcome, themarginofnormal tissue required,
and the long-termdisease-control outcomes. In addition, the
encouraging results of focal therapy that we report here are
the outcomes of a few experienced centres; their generaliz-
ability has yet to be proven and training and quality control
will be key factors driving the dissemination further.
Finally, we did not address the level of evidence that
should drive change. In the studies included, no prospective
development study was powered on oncologic outcome,
and only two series had a follow-up >5 yr; therefore, no
significant conclusion on disease control could be derived.
Certainly, high-quality effectiveness studies comparing
focal therapy to standard treatments (level 1 evidence)
are needed to change practice.
The design of future effectiveness trials comparing focal
to whole-gland therapies is debatable. Some have argued
for long-termmortality outcomes; however, if this were the
case, progress and change would be prohibitively delayed
because the studies required for mortality outcomes are
likely to take 15–20 yr to deliver data and unlikely to
recruit. If mortality is out of reach and biochemical
outcomes are implausible, at least for the time being, then
other more pragmatic outcomes will be necessary. These
E U RO P E AN URO LOG Y 6 6 ( 2 0 1 4 ) 7 3 2 – 7 5 1748are likely to include (1) treatment-specific and overall QOL
measures, (2) local cancer control measured as absence of
significant PCa, (3) rate of additional systemic therapy, and
(4) cost effectiveness.
The first pragmatic outcome relates to treatment-related
side effects and can be relatively well captured in
the short term using validated questionnaires. These are
principally directed at genitourinary and bowel-associated
outcomes and have been used in the evaluation of all the
interventions under consideration. The second pragmatic
outcome relates to effectiveness of local cancer control.
Histologic confirmation of complete ablation within the
treated area appears to be essential when a man is treated
with focal therapy, given the uncertainty of PSA follow-up.
However, TRUS biopsy would have the same inherent
random and systematic sampling errors when used after
treatment and may not be reliable in determining the
absence of residual disease. At present, TTMB appears to be
one of a number of accurate tools for confirming the
effectiveness of the treatment, as the possibility of missing
significant PCa is <5% with this technique [72]. In contrast,
some investigators have used mpMRI to assess recurrence
and the initial results seem promising. In two studies of
patients treated with focal HIFU, one including 20 patients
and the other 41, no significant cancer was found in the
treated area when mpMRI did not show signs of residual
disease [30,35].
The third pragmatic outcome, use of additional systemic
therapy, could be regarded as the only acceptable outcome
measure that would cover focal therapy and standard care
objectively. This outcome should clearly be separated from
the need for additional local treatment or local failure.
Indeed, secondary ablation with the same or a different
energy applied in a focal manner probably should not be
incorporated in this pragmatic outcome as a failure
although the application of whole-gland therapy using
any modality would constitute failure at that point in time.
In other words, this pragmatic outcome should count as
failure when there is a change in strategy from focal to
whole-gland ablation or the direct shift to systemic
therapy; this would allow realistic comparison with
standard treatments. This would have to be verified by
evidence that men who have second or even third focal
treatments do not suffer worse genitourinary and disease-
control rates compared to men who have radical treat-
ments. Finally, the effectiveness of each therapy should be
balanced with its cost to allow objective comparisons
between different active treatments.
5. Conclusions
Although focal therapymay be regarded as an alternative to
active surveillance by many physicians, it should not be
proposed to patients with confirmed, clinically insignifi-
cant, low-risk disease who are unlikely to benefit from any
formof treatment and inwhomeven focal therapywould be
regarded as an overtreatment. Robust effectiveness studies
are now required to compare focal therapy to radical
therapy in men with clinically significant PCa.Author contributions: Massimo Valerio and Hashim U. Ahmed had full
access to all the data in the study and take responsibility for the integrity
of the data and the accuracy of the data analysis.
Study concept and design: Valerio, Ahmed, Emberton, Lawrentschuk,
Lazzeri, Montironi, Nguyen, Trachtenberg, Polascik.
Acquisition of data: Valerio, Ahmed.
Analysis and interpretation of data: Valerio, Ahmed, Emberton, Law-
rentschuk, Lazzeri, Montironi, Nguyen, Trachtenberg, Polascik.
Drafting of the manuscript: Valerio, Ahmed.
Critical revision of the manuscript for important intellectual content:
Valerio, Ahmed, Emberton, Lawrentschuk, Lazzeri, Montironi, Nguyen,
Trachtenberg, Polascik.
Statistical analysis: None.
Obtaining funding: None.
Administrative, technical, or material support: Emberton, Lawrentschuk,
Lazzeri, Montironi, Nguyen, Trachtenberg, Polascik.
Supervision: None.
Other (specify): None.
Financial disclosures: Massimo Valerio certiﬁes that all conﬂicts of
interest, including speciﬁc ﬁnancial interests and relationships and
afﬁliations relevant to the subject matter or materials discussed in the
manuscript (eg, employment/afﬁliation, grants or funding, consultan-
cies, honoraria, stock ownership or options, expert testimony, royalties,
or patents ﬁled, received, or pending), are the following: The SICPA
foundation supports the ongoing fellowship and PhD program of
M. Valerio. M. Emberton and H.U. Ahmed would like to acknowledge
funding from the Medical Research Council (UK), the Pelican Cancer
Foundation charity, Prostate Cancer UK, St Peters Trust charity, Prostate
Cancer Research Centre, theWellcome Trust, National Institute of Health
Research-Health Technology Assessment program, and the US National
Institutes of Health National Cancer Institute. M. Emberton receives
funding in part from the UK National Institute of Health Research UCLH/
UCL Comprehensive Biomedical Research Centre. M. Emberton and H.U.
Ahmed receive funding from USHIFU, GSK and Advanced Medical
Diagnostics for clinical trials. M. Emberton is a paid consultant to Steba
Biotech and USHIFU. Both have previously received consultancy
payments from Oncura/GE Healthcare and Steba Biotech.
Funding/Support and role of the sponsor: None.
Acknowledgment statement: The authors acknowledge the participation
of the following investigators: Rajiv Chopra, Cosimo De Nunzio, Louise
Dickinson, Shigeo Horie, Uri Lindner, Stephan Madersbacher, Caroline M.
Moore, Re´mi Souchon, Osamu Ukimura, John F. Ward, and Alexandre R.
Zlotta.
References
[1] Wilt TJ, Brawer MK, Jones KM, et al. Radical prostatectomy versus
observation for localized prostate cancer. N Engl J Med 2012;367:
203–13.
[2] Ficarra V, Novara G, Rosen RC, et al. Systematic review and meta-
analysis of studies reporting urinary continence recovery after
robot-assisted radical prostatectomy. Eur Urol 2012;62:405–17.
[3] Ficarra V, Novara G, Ahlering TE, et al. Systematic review and
meta-analysis of studies reporting potency rates after robot-
assisted radical prostatectomy. Eur Urol 2012;62:418–30.
[4] Resnick MJ, Koyama T, Fan KH, et al. Long-term functional out-
comes after treatment for localized prostate cancer. N Engl J Med
2013;368:436–45.
[5] Sheets NC, Goldin GH, Meyer AM, et al. Intensity-modulated
radiation therapy, proton therapy, or conformal radiation therapy
and morbidity and disease control in localized prostate cancer.
JAMA 2012;307:1611–20.
E U RO P E AN URO L OGY 6 6 ( 2 0 1 4 ) 7 3 2 – 7 5 1 749[6] Lindner U, Trachtenberg J, Lawrentschuk N. Focal therapy in
prostate cancer: modalities, ﬁndings and future considerations.
Nat Rev Urol 2010;7:562–71.
[7] De la Rosette J, Ahmed H, Barentsz J, et al. Focal therapy in prostate
cancer-report from a consensus panel. J Endourol 2010;24:775–80.
[8] Eggener S, Salomon G, Scardino PT, De la Rosette J, Polascik TJ,
Brewster S. Focal therapy for prostate cancer: possibilities and
limitations. Eur Urol 2010;58:57–64.
[9] Ahmed HU, Pendse D, Illing R, Allen C, van der Meulen JH, Ember-
ton M. Will focal therapy become a standard of care for men with
localized prostate cancer? Nat Clin Pract Oncol 2007;4:632–42.
[10] Liu W, Laitinen S, Khan S, et al. Copy number analysis indicates
monoclonal origin of lethal metastatic prostate cancer. Nat Med
2009;15:559–65.
[11] McCulloch P, Altman DG, Campbell WB, et al. No surgical innova-
tion without evaluation: the IDEAL recommendations. Lancet
2009;374:1105–12.
[12] Oxford Centre for Evidence-based Medicine - levels of evidence
(March 2009). Oxford Centre for Evidence-Based Medicine Web
Site. http://www.cebm.net/?o=1025. Accessed December 14, 2012.
[13] McCulloch P. The IDEAL recommendations and urological innova-
tion. World J Urol 2011;29:331–6.
[14] Novara G, Ficarra V, Rosen RC, et al. Systematic review and meta-
analysis of perioperative outcomes and complications after robot-
assisted radical prostatectomy. Eur Urol 2012;62:431–52.
[15] Madersbacher S, Pedevilla M, Vingers L, Susani M, Marberger M.
Effect of high-intensity focused ultrasound on human prostate
cancer in vivo. Cancer Res 1995;55:3346–51.
[16] Zlotta AR, Djavan B, Matos C, et al. Percutaneous transperineal
radiofrequency ablation of prostate tumour: safety, feasibility and
pathological effects on human prostate cancer. Br J Urol 1998;
81:265–75.
[17] Beerlage HP, Thuroff S, Debruyne FM, Chaussy C, de la Rosette JJ.
Transrectal high-intensity focused ultrasound using the Ablatherm
device in the treatment of localized prostate carcinoma. Urology
1999;54:273–7.
[18] Souchon R, Rouviere O, Gelet A, et al. Visualisation of HIFU lesions
using elastography of the human prostate in vivo: preliminary
results. Ultrasound Med Biol 2003;29:1007–15.
[19] Moore CM, Nathan TR, LeesWR, et al. Photodynamic therapy using
meso tetra hydroxy phenyl chlorin (mTHPC) in early prostate
cancer. Lasers Surg Med 2006;38:356–63.
[20] Bahn DK, Silverman P, Lee Sr F, Badalament R, Bahn ED, Rewcastle
JC. Focal prostate cryoablation: initial results show cancer control
and potency preservation. J Endourol 2006;20:688–92.
[21] Onik G, Vaughan D, Lotenfoe R, Dineen M, Brady J. ‘‘Male lumpec-
tomy’’: focal therapy for prostate cancer using cryoablation. Urol-
ogy 2007;70(Suppl):16–21.
[22] Ellis DS, Manny Jr TB, Rewcastle JC. Focal cryosurgery followed by
penile rehabilitation as primary treatment for localized prostate
cancer: initial results. Urology 2007;70(Suppl):9–15.
[23] Muto S, Yoshii T, Saito K, Kamiyama Y, Ide H, Horie S. Focal therapy
with high-intensity-focused ultrasound in the treatment of local-
ized prostate cancer. Jpn J Clin Oncol 2008;38:192–9.
[24] Murat FJ, Cherasse A, Poissonier L, et al. Focal therapy of prostate
cancer (PCa)with HIFU: inﬂuence on erectile dysfunction (ED). Eur
Urol Suppl 2009;8:334.
[25] Lindner U, Weersink RA, Haider MA, et al. Image guided photo-
thermal focal therapy for localized prostate cancer: phase I trial. J
Urol 2009;182:1371–7.
[26] Lindner U, Lawrentschuk N, Weersink RA, et al. Focal laser abla-
tion for prostate cancer followed by radical prostatectomy: vali-
dation of focal therapy and imaging accuracy. Eur Urol 2010;
57:1111–4.[27] Raz O, Haider MA, Davidson SRH, et al. Real-time magnetic reso-
nance imaging-guided focal laser therapy in patients with low-
risk prostate cancer. Eur Urol 2010;58:173–7.
[28] TruesdaleMD,CheethamPJ,HrubyGW,etal.Anevaluationofpatient
selection criteria on predicting progression-free survival after pri-
maryfocalunilateralnerve-sparingcryoablationforprostatecancer:
recommendations for follow up. Cancer J 2010;16:544–9.
[29] El Fegoun AB, Barret E, Prapotnich D, et al. Focal therapywith high-
intensity focused ultrasound for prostate cancer in the elderly. A
feasibility study with 10 years follow-up. Int Braz J Urol 2011;
37:213–9; discussion 220–2.
[30] Ahmed HU, Freeman A, Kirkham A, et al. Focal therapy for
localized prostate cancer: a phase I/II trial. J Urol 2011;185:
1246–54.
[31] Ward JF, Jones JS. Focal cryotherapy for localized prostate cancer: a
report from the national Cryo On-Line Database (COLD) Registry.
BJU Int 2012;109:1648–54.
[32] Tay KJ, Cheng C, Kwek JW, et al. Initial experience with MRgFUS
focal therapy for low-risk prostate cancer. J Endourol 2011;25:
A99–100.
[33] Chopra R, Colquhoun A, Burtnyk M, et al. MR imaging-controlled
transurethral ultrasound therapy for conformal treatment of
prostate tissue: initial feasibility in humans. Radiology 2012;265:
303–13.
[34] Bahn D, de Castro Abreu AL, Gill IS, et al. Focal cryotherapy
for clinically unilateral, low-intermediate risk prostate cancer in
73 men with a median follow-up of 3.7 years. Eur Urol 2012;62:
55–63.
[35] Ahmed HU, Hindley RG, Dickinson L, et al. Focal therapy for
localised unifocal and multifocal prostate cancer: a prospective
development study. Lancet Oncol 2012;13:622–32.
[36] Dickinson L, Ahmed HU, McCartan N, et al. Medium term out-
comes following primary focal therapy using HIFU for localised
prostate cancer. BJU Int 2012;109(Suppl S7):6.
[37] Nguyen PL, Chen MH, Zhang Y, et al. Updated results of magnetic
resonance imaging guided partial prostate brachytherapy for
favorable risk prostate cancer: implications for focal therapy.
J Urol 2012;188:1151–6.
[38] Napoli A, Anzidei M, De Nunzio C, et al. Real-time magnetic
resonance-guided high-intensity focused ultrasound focal therapy
for localisedprostate cancer: preliminary experience. EurUrol2013;
63:395–8.
[39] Barret E, Ahallal Y, Sanchez-Salas R, et al. Morbidity of focal
therapy in the treatment of localized prostate cancer. Eur Urol
2013;63:618–22.
[40] Shariat SF, Raptidis G, Masatoschi M, Bergamaschi F, Slawin KM.
Pilot study of radiofrequency interstitial tumor ablation (RITA) for
the treatment of radio-recurrent prostate cancer. Prostate 2005;
65:260–7.
[41] Nguyen PL, Chen MH, D’Amico AV, et al. Magnetic resonance
image-guided salvage brachytherapy after radiation in select
men who initially presented with favorable-risk prostate cancer:
a prospective phase 2 study. Cancer 2007;110:1485–92.
[42] Eisenberg ML, Shinohara K. Partial salvage cryoablation of the
prostate for recurrent prostate cancer after radiotherapy failure.
Urology 2008;72:1315–8.
[43] Ahmed HU, Cathcart P, McCartan N, et al. Focal salvage therapy for
localized prostate cancer recurrence after external beam radio-
therapy: a pilot study. Cancer 2012;118:4148–55.
[44] Abreu ALDC, Ahmadi H, Leslie S, et al. Salvage focal versus salvage
total cryoablation for radio-recurrent prostate cancer: cancer
control and harm-reduction. J Endourol 2011;26:A208.
[45] Eggener S. A pilot study to evaluate magnetic resonance thermal
image-guided laser-induced interstitial thermal therapy for focal
E U RO P E AN URO LOG Y 6 6 ( 2 0 1 4 ) 7 3 2 – 7 5 1750ablation of prostate cancer [ClinicalTrials.gov identiﬁer NCT0
1192438]. Clinicaltrials.gov Web site. http://clinicaltrials-lhc.
nlm.nih.gov/ct2/show/study/NCT01192438?view=results.
[46] Taneja S. A prospective, multicenter phase I/II safety and tolera-
bility study of unilateral vascular-targeted photodynamic therapy
using WST11 in patients with localized prostate cancer [Clinical-
Trials.gov identiﬁer NCT00946881]. Clinicaltrials.gov Web site.
http://clinicaltrials.gov/show/NCT00946881.
[47] Emberton M. Vascular-targeted photodynamic therapy using
WST11 in patients with localized prostate cancer [ClinicalTrials.
gov identiﬁer NCT00975429]. Clinicaltrials.gov Web site. http://
clinicaltrials.gov/ct2/show/NCT00975429?term=NCT00975429&
rank=1.
[48] Emberton M. A European randomised phase 3 study to assess
the efﬁcacy and safety of TOOKAD1 Soluble for localised prostate
cancer compared to active surveillance [ClinicalTrials.gov identiﬁer
NCT01310894]. ClinicalTrials.govWeb site. http://clinicaltrials. gov/
show/NCT01310894.
[49] Emberton M. A multi-center prospective single arm intervention
trial evaluating focal therapy using high intensity focused ultra-
sound (Sonablate 500) for localized prostate cancer [Clinical-
Trials.gov identiﬁer NCT01194648]. ClinicalTrials.gov Web site.
http://clinicaltrials.gov/ct2/show/NCT01194648?term=NC-
T01194648&rank=1.
[50] Ahmed HU. An evaluation of lesion control using focal ablation
with high intensity focused ultrasound in the treatment of non-
metastatic progressive prostate cancer [ClinicalTrials.gov identiﬁer
NCT00987675]. ClinicalTrials.govWeb site. http://clinicaltrials.gov/
ct2/show/NCT00987675?term=NCT00987675&rank=1.
[51] Guazzoni G. Focal therapy for organ conﬁned prostate cancer: an
investigative prospective pilot study [ClinicalTrials.gov identiﬁer
NCT00928603]. ClinicalTrials.gov Web site. http://clinicaltrials.
gov/ct2/show/NCT00928603?term=NCT00928603&rank=1.
[52] Napoli A. Focal therapy with magnetic resonance guided focused
ultrasound treatment of locally non-advanced prostate cancer:
phase 1 study [ClinicalTrials.gov identiﬁer NCT01522118]. Clinical
Trials.gov Web site. http://clinicaltrials.gov/ct2/show/NCT01522
118?term=NCT01522118&rank=1.
[53] Zelefsky M. Phase II study assessing the potential for reduced
toxicity using focal brachytherapy early stage, low volume in pros-
tate cancer [ClinicalTrials.gov identiﬁer NCT01354951]. Clinical
Trials.gov Web site. http://clinicaltrials.gov/ct2/show/NCT0135
4951?term=NCT01354951&rank=1.
[54] Ward JF. Regional cryoablation for localized adenocarcinoma of the
prostate [ClinicalTrials.gov identiﬁer NCT00877682]. ClinicalTrials.
gov Web site. http://clinicaltrials.gov/ct2/show/NCT00877682?
term=NCT00877682&rank=1.
[55] Eastham J. A phase II study of focal cryoablation in low-risk prostate
cancer [ClinicalTrials.gov identiﬁer NCT00774436]. ClinicalTrials.
gov Web site. http://clinicaltrials.gov/ct2/show/NCT00774436?
term=NCT00774436&rank=1.
[56] Emberton M. A prospective development study evaluating
focal therapy using irreversible electroporation (Nanoknife1)
in men with localised prostate cancer [ClinicalTrials.gov identi-
ﬁer NCT01726894]. ClinicalTrials.gov Web site. http://clinical-
trials. gov/ct2/show/NCT01726894?term=NCT01726894&
rank=1.
[57] Chung H. Pilot study of focal salvage HDR prostate brachytherapy
[ClinicalTrials.gov identiﬁer NCT01583920]. ClinicalTrials.govWeb
site. http://clinicaltrials.gov/ct2/show/NCT01583920?term=
NCT01583920&rank=1.
[58] Eggener SE, Scardino PT, Carroll PR, et al. Focal therapy for local-
ized prostate cancer: a critical appraisal of rationale and modali-
ties. J Urol 2007;178:2260–7.[59] Langley S, Ahmed HU, Al-Qaisieh B, et al. Report of a consensus
meeting on focal low dose rate brachytherapy for prostate cancer.
BJU Int 2012;109(Suppl 1):7–16.
[60] Ahmed HU, Akin O, Coleman JA, et al. Transatlantic consensus
group on active surveillance and focal therapy for prostate cancer.
BJU Int 2012;109:1636–47.
[61] Bostwick DG, Waters DJ, Farley ER, et al. Group consensus reports
from the Consensus Conference on Focal Treatment of Prostatic
Carcinoma, Celebration, Florida, February 24, 2006. Urology 2007;
70(Suppl):42–4.
[62] Mayes JM, Mouraviev V, Sun L, Tsivian M, Madden JF, Polascik TJ.
Can the conventional sextant prostate biopsy accurately predict
unilateral prostate cancer in low-risk, localized, prostate cancer?
Urol Oncol 2011;29:166–70.
[63] Berg KD, Toft BG, Roder MA, Brasso K, Vainer B, Iversen P. Is it
possible to predict low-volume and insigniﬁcant prostate cancer
by core needle biopsies? APMIS 2013;121:257–65.
[64] Sinnott M, Falzarano SM, Hernandez AV, et al. Discrepancy in
prostate cancer localization between biopsy and prostatectomy
specimens in patients with unilateral positive biopsy: implica-
tions for focal therapy. Prostate 2012;72:1179–86.
[65] Gallina A, Maccagnano C, Suardi N, et al. Unilateral positive
biopsies in low risk prostate cancer patients diagnosed with
extended transrectal ultrasound-guided biopsy schemes do not
predict unilateral prostate cancer at radical prostatectomy. BJU Int
2012;110:E64–8.
[66] Washington SL, Bonham M, Whitson JM, Cowan JE, Carroll PR.
Transrectal ultrasonography-guided biopsy does not reliably iden-
tify dominant cancer location in men with low-risk prostate
cancer. BJU Int 2012;110:50–5.
[67] Katz B, Srougi M, Dall’Oglio M, et al. Are we able to correctly
identify prostate cancer patients who could be adequately treated
by focal therapy? Urol Oncol 2012;30:794–7.
[68] Tsivian M, Moreira DM, Sun L, et al. Biopsy accuracy in identifying
unilateral prostate cancer depends on prostate weight. Urol Oncol
2012;30:21–5.
[69] Tsivian M, Kimura M, Sun L, Mouraviev V, Mayes JM, Polascik TJ.
Predicting unilateral prostate cancer on routine diagnostic biopsy:
sextant vs extended. BJU Int 2010;105:1089–92.
[70] Polascik TJ, Mayes JM, Schroeck FR, et al. Patient selection for
hemiablative focal therapy of prostate cancer: variables predictive
of tumor unilaterality based upon radical prostatectomy. Cancer
2009;115:2104–10.
[71] Losa A, Gadda GM, Lazzeri M, et al. Complications and quality of
life after template-assisted transperineal prostate biopsy in
patients eligible for focal therapy. Urology 2013;81:1291–6.
[72] Crawford ED, Rove KO, Barqawi AB, et al. Clinical-pathologic
correlation between transperineal mapping biopsies of the pros-
tate and three-dimensional reconstruction of prostatectomy spe-
cimens. Prostate 2013;73:778–87.
[73] Long JA, Hungr N, BaumannM, et al. Development of a novel robot
for transperineal needle based interventions: focal therapy,
brachytherapy and prostate biopsies. J Urol 2012;188:1369–74.
[74] Hossack T, Patel MI, Huo A, et al. Location and pathological
characteristics of cancers in radical prostatectomy specimens
identiﬁed by transperineal biopsy compared to transrectal biopsy.
J Urol 2012;188:781–5.
[75] Huo AS, Hossack T, Symons JL, et al. Accuracy of primary system-
atic template guided transperineal biopsy of the prostate for
locating prostate cancer: a comparisonwith radical prostatectomy
specimens. J Urol 2012;187:2044–9.
[76] Hu Y, Ahmed HU, Carter T, et al. A biopsy simulation study to
assess the accuracy of several transrectal ultrasonography (TRUS)-
biopsy strategies compared with template prostate mapping
E U RO P E AN URO L OGY 6 6 ( 2 0 1 4 ) 7 3 2 – 7 5 1 751biopsies in patients who have undergone radical prostatectomy.
BJU Int 2012;110:812–20.
[77] Ahmed HU, Hu Y, Carter T, et al. Characterizing clinically signiﬁ-
cant prostate cancer using template prostate mapping biopsy.
J Urol 2011;186:458–64.
[78] Barqawi AB, Rove KO, Gholizadeh S, O’Donnell CI, Koul H,
Crawford ED. The role of 3-dimensional mapping biopsy in deci-
sion making for treatment of apparent early stage prostate
cancer. J Urol 2011;186:80–5.
[79] Onik G, Miessau M, Bostwick DG. Three-dimensional prostate
mapping biopsy has a potentially signiﬁcant impact on prostate
cancer management. J Clin Oncol 2009;27:4321–6.
[80] Puech P, Potiron E, Lemaitre L, et al. Dynamic contrast-enhanced-
magnetic resonance imaging evaluation of intraprostatic prostate
cancer: correlation with radical prostatectomy specimens. Urology
2009;74:1094–9.
[81] Villers A, Puech P, Mouton D, Leroy X, Ballereau C, Lemaitre L.
Dynamic contrast enhanced, pelvic phased array magnetic reso-
nance imaging of localized prostate cancer for predicting tumor
volume: correlation with radical prostatectomy ﬁndings. J Urol
2006;176:2432–7.
[82] Simmons LA, Autier P, Zat’ura F, et al. Detection, localisation and
characterisation of prostate cancer by prostate HistoScanning(TM).
BJU Int 2012;110:28–35.
[83] Zhu Y, Chen Y, Qi T, et al. Prostate cancer detection with real-time
elastography using a bi-plane transducer: comparison with step
section radical prostatectomy pathology. World J Urol 2014;
32:329–33.
[84] Gulley JL, Emberton M, Kurhanewicz J, Choyke P. Progress in
prostate cancer imaging. Urol Oncol 2012;30:938–9.
[85] Smeenge M, de la Rosette JJ, Wijkstra H. Current status of trans-
rectal ultrasound techniques in prostate cancer. Curr Opin Urol
2012;22:297–302.
[86] Humphrey PA. Complete histologic serial sectioning of a pros-
tate gland with adenocarcinoma. Am J Surg Pathol 1993;17:
468–72.
[87] Piersanti M, Ezzat S, Asa SL. Controversies in papillary microcar-
cinoma of the thyroid. Endocr Pathol 2003;14:183–91.
[88] Allegra CJ, Aberle DR, Ganschow P, et al. National Institutes of
Health State-of-the-Science Conference statement: diagnosis and
management of ductal carcinoma in situ September 22–24, 2009.
J Natl Cancer Inst 2010;102:161–9.
[89] Graversen JA,Mues AC, Perez-Lanzac de Lorca A, Landman J. Active
surveillance of renal cortical neoplasms: a contemporary review.
Postgrad Med 2011;123:105–13.
[90] Jones TD, Cheng L. Papillary urothelial neoplasm of lowmalignant
potential: evolving terminology and concepts. J Urol 2006;175:
1995–2003.
[91] Nevoux P, Ouzzane A, Ahmed HU, et al. Quantitative tissue anal-
yses of prostate cancer foci in an unselected cystoprostatectomy
series. BJU Int 2012;110:517–23.
[92] Catto JW, Robinson MC, Albertsen PC, et al. Suitability of PSA-
detected localised prostate cancers for focal therapy: experience
from the ProtecT study. Br J Cancer 2011;105:931–7.
[93] Mouraviev V, Villers A, Bostwick DG, Wheeler TM, Montironi R,
PolascikTJ.Understandingthepathological featuresof focality,grade
andtumourvolumeofearly-stageprostatecancerasafoundation for
parenchyma-sparing prostate cancer therapies: active surveillance
and focal targeted therapy. BJU Int 2011;108:1074–85.
[94] Masterson TA, Cheng L, Koch MO. Pathological characterization of
unifocal prostate cancers in whole-mount radical prostatectomy
specimens. BJU Int 2011;107:1587–91.
[95] Polascik TJ, Mayes JM, Sun L, Madden JF, Moul JW, Mouraviev V.
Pathologic stage T2a and T2b prostate cancer in the recentprostate-speciﬁc antigen era: implications for unilateral ablative
therapy. Prostate 2008;68:1380–6.
[96] Mouraviev V, Mayes JM, Sun L, Madden JF, Moul JW, Polascik TJ.
Prostate cancer laterality as a rationale of focal ablative therapy for
the treatment of clinically localized prostate cancer. Cancer 2007;
110:906–10.
[97] Mouraviev V, Mayes JM, Madden JF, Sun L, Polascik TJ. Analysis of
laterality and percentage of tumor involvement in 1386 prosta-
tectomized specimens for selection of unilateral focal cryothera-
py. Technol Cancer Res Treat 2007;6:91–5.
[98] Karavitakis M, Ahmed HU, Abel PD, Hazell S, Winkler MH. An-
atomically versus biologically unifocal prostate cancer: a patho-
logical evaluation in the context of focal therapy. Ther Adv Urol
2012;4:155–60.
[99] Ward JF, Nakanishi H, Pisters L, Babaian RJ, Troncoso P. Cancer
ablation with regional templates applied to prostatectomy speci-
mens frommen who were eligible for focal therapy. BJU Int 2009;
104:490–7.
[100] Bott SR, Ahmed HU, Hindley RG, Abdul-Rahman A, Freeman A,
EmbertonM. The index lesion and focal therapy: an analysis of the
pathological characteristics of prostate cancer. BJU Int 2010;106:
1607–11.
[101] Mazzucchelli R, Scarpelli M, Cheng L, et al. Pathology of prostate
cancer and focal therapy (‘male lumpectomy’). Anticancer Res
2009;29:5155–61.
[102] Algaba F, Montironi R. Impact of prostate cancer multifocality on
its biology and treatment. J Endourol 2010;24:799–804.
[103] Ahmed HU. The index lesion and the origin of prostate cancer. N
Engl J Med 2009;361:1704–6.
[104] Lin D, Bayani J, Wang Y, et al. Development of metastatic and non-
metastatic tumor lines from a patient’s prostate cancer specimen—
identiﬁcation of a small subpopulationwithmetastatic potential in
the primary tumor. Prostate 2010;70:1636–44.
[105] Wise AM, Stamey TA, McNeal JE, Clayton JL. Morphologic and
clinical signiﬁcance of multifocal prostate cancers in radical pros-
tatectomy specimens. Urology 2002;60:264–9.
[106] Stamey TA, Freiha FS, McNeal JE, Redwine EA, Whittemore AS,
Schmid HP. Localized prostate cancer. Relationship of tumor
volume to clinical signiﬁcance for treatment of prostate cancer.
Cancer 1993;71(Suppl):933–8.
[107] Wolters T, Roobol MJ, van Leeuwen PJ, et al. A critical analysis of
the tumor volume threshold for clinically insigniﬁcant prostate
cancer using a data set of a randomized screening trial. J Urol
2011;185:121–5.
[108] Van der Kwast TH. The trade-off between sensitivity and speciﬁc-
ity of clinical protocols for identiﬁcation of insigniﬁcant prostate
cancer. Eur Urol 2012;62:469–71.
[109] Grasso CS, Wu YM, Robinson DR, et al. The mutational landscape
of lethal castration-resistant prostate cancer. Nature 2012;487:
239–43.
[110] Ganz PA, Barry JM, Burke W, et al. NIH State-of-the-Science
Conference Statement: role of active surveillance in the manage-
ment of menwith localized prostate cancer. NIH Consens State Sci
Statements 2011;28:1–27.
[111] Roach III M, Hanks G, Thames Jr H, et al. Deﬁning biochemical
failure following radiotherapy with or without hormonal therapy
in men with clinically localized prostate cancer: recommenda-
tions of the RTOG-ASTRO Phoenix Consensus Conference. Int J
Radiat Oncol Biol Phys 2006;65:965–74.
[112] Ganzer R, Robertson CN, Ward JF, et al. Correlation of prostate-
speciﬁc antigen nadir and biochemical failure after high-intensity
focused ultrasound of localized prostate cancer based on the Stutt-
gart failure criteria—analysis from the @-Registry. BJU Int 2011;
108:E196–201.
